Conference call and webcast to begin at 8:00 AM ET
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
Conference Call and Webcast Information:
Date: Thursday, November 14, 2024, at 8:00 AM ET
Participant Dial-In (U.S.): 1 (877) 407-9039
Participant Dial-in (International): 1 (201) 689-8470
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced their planned presence at the International Society for Pharmacoeconomics…
CARLSBAD, Calif.--(BUSINESS WIRE)--#Carlsmed--Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery…
Company’s ECG-AI algorithm enables earlier heart failure detection CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leading artificial intelligence…
Stockholm, Sweden--(Newsfile Corp. - November 6, 2024) - Tress Wellness, creator of Amazon's top-rated at-home…
LOS ANGELES, Nov. 6, 2024 /PRNewswire/ -- Molecular Instruments® (MI), the inventor of the HCR™ Imaging…
Research demonstrates hospitals using Force Therapeutics care management platform benefit from significantly lower excess readmissions,…